Phase I trial of concurrent administration of topotecan and docetaxel for cancer treatment

Journal of Applied Research

Volumn 5, Issue 1, 2005, Pages 53-60

  Ishmael, D Richard ^a   Liu, Hong ^b   Nordquist, John A ^c   Nordquist, Robert E ^c   Chen, Wei R ^d  

^a Natcel Dev/Cancer Treatm Center   (United States)

^b UNIVERSITY OF OKLAHOMA   (United States)

^c Wound Healing of Oklahoma   (United States)

^d UNIVERSITY OF CENTRAL OKLAHOMA   (United States)

Author keywords

Cancer treatment; Combination therapy; Docetaxel; Phase clinical trial; Synergistic effect; Topotecan

Indexed keywords

DOCETAXEL; TOPOTECAN;

ANEMIA; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG INFUSION; HUMAN; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; THROMBOCYTOPENIA;

EID: 17044388497     PISSN: 1537064X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Ishmael DR, Nordquist JA, Hamilton JA, Nordquist RE. Detection of chemotherapeutic synergism through pre-clinical testing and its application in the design of phase I human clinical trial. AACR-NCI-EORTC International Conference 1999; Washington DC. Abstract 529.
2. Ishmael DR, Nordquist JA, Nordquist RE. Docetaxel - attempts through pre-clinical testing to improve its efficacy [Abstract]. Proc Am Assoc Cancer Res. 2001;42:370. Abstract 1995.
3. Verweij J, Clavel M, Chevalier B. Pacitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind. Ann Oncol. 1994;5:495-505.
4. Hainsworth JD, Burris HA, Erland JB, Thomas M, Greco FA. Phase I trial of Docetaxeladministered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol. 1998;16:2164-2168.
5. Bissery M-C, Vrignaud P, Lavelle F. Pre-clinical profile of Docetaxel (Taxotere): efficacy as a single agent and in combination. Semin Oncol. 1995;22:3-16.
6. Milla-Santos A, Milla L, Rallo L, Solano V. High-dose epirubicin plus docetaxel at standard dose with lenograstim support as first-line therapy in advanced breast cancer. Am J Clin Oncol. 2001;24:138-142.
7. Scheithauer W, Depisch D, Haider K, et al. Treatment of advanced, refractory breast cancer with alternating docetaxel and epirubicin/ cyclophosphamide plus human granulocyte colony-stimulating factor. Breast Cancer Res Treatment. 2000;63:235-241.
8. Georgoulias V, Kouroussis C, Androulakis N. et al. Front-line treatment of advanced non-small-cell lung cancer with docetaxel and gemcitabine: a multicenter phase II trial. J Clin Oncol. 1999;17:914-920.
9. Williams JF, Muenchen HJ, Kamradt JM, et al. Treatment of androgen-independent prostate cancer using antimicrotubule agents docetaxel and estramustine in combination: an experimental study. Prostate. 2000;44:275-278.
10. Janinis J, Papadakou M, Xidakis E, et al. Combination chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in previously treated patients with advanced/recurrent head and neck cancer: a phase II feasibility study. Am J Clin Oncol. 2000;23:128-131.
11. Gunthert AR, Pilz S, Kuhn W, et al. Docetaxel is effective in the treatment of metastatic endometrial cancer. Anticancer Res. 1999;19:3459-3461.
12. Androulakis N, Kourousis C, Dimopoulos MA, et al. Treatment of pancreatic cancer with docetaxel and granulocyte colony-stimulating factor: a multicenter phase II study. J Clin Oncol. 1999;17:1779-1785.
13. Sinibaldi VJ, Carducci M, Laufer M, et al. Preliminary evaluation of a short course of estramustine phosphate and docetaxel (Taxotere) in the treatment of hormone-refractory prostate cancer. Semin Oncol. 1999;26:45-48.
14. Zamboni C, Egorin M, Van Echo D, et al. Pharmacokinetic and pharmacodynamic study of the combination of docetaxel and topotecan in patients with solid tumors. J Clin Oncol. 2000;18:3288-3294.
15. Ringel I. Horwitz S. Studies with RP 56976 (Taxotere): a semisynthetic analogue of taxol. J Natl Cancer Inst. 1991;83:288-291.
16. Kingsbury W, Hertzberg R, Beuhm T, et al. Clinical synthesis and structure-activity relationships related to SSFK 104864, a novel water-soluble analog of camptothecin. Proc Am Assoc Cancer Res. 1989;30:622.
17. Hsiang Y, Lihou M, Liu L. Arrest of replication forks by drug stabilized topoisomerase I DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res. 1989;9:5077-5082.
18. Eisenhauer E, Hoskins P, Beare S, et al. Randomized phase II study of two schedules of topotecan in previously treated epithelial ovarian cancer. Proc Am Soc Clin Oncol. 1997;19:A1249.
19. Eastern Cooperative Oncology Group (ECOG). Performance Status. From Oken MM, Creech RH, Tormey DC, et al. Toxicity and Response Criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol. 1982;5:649-655 Available at: http://www.ecog.org/~ecogdba/general/perf_stat.html. Accessed November 12, 1998.
20. Eastern Cooperative Oncology Group (ECOG). Common Toxicity Criteria. From Oken, M.M., Creech, R.H., Tormey, D.C. et al. Toxicity and Response Criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol. 1982; 5:649-655. Available at: http://www.ecog.org/~ecogdba/general/common_tox.html. Accessed November 11,1998.